PIN1 and cancer: Yang and collogues developed an improved, controlled-release formulation of ATRA (ATRA-PLLA microparticles) that demonstrated selectivity for Pin1 inhibition and improved anti-cancer efficacy in xenografts of hepatocellular carcinoma, a cancer that is enhanced by Pin1 [151].